Annexon (NASDAQ:ANNX – Get Rating) had its price target reduced by Cantor Fitzgerald from $22.00 to $18.00 in a research report report published on Tuesday morning, The Fly reports.
Other equities research analysts have also issued reports about the company. Needham & Company LLC reiterated a buy rating and set a $24.00 price target on shares of Annexon in a report on Tuesday, March 7th. HC Wainwright reiterated a buy rating and set a $30.00 price target on shares of Annexon in a report on Tuesday, March 7th. Five investment analysts have rated the stock with a buy rating, According to MarketBeat, the stock has an average rating of Buy and a consensus target price of $19.80.
Annexon Price Performance
NASDAQ:ANNX opened at $4.49 on Tuesday. Annexon has a fifty-two week low of $2.06 and a fifty-two week high of $7.65. The stock’s 50-day moving average is $5.96 and its two-hundred day moving average is $5.75. The stock has a market cap of $226.70 million, a PE ratio of -1.56 and a beta of 0.53.
Institutional Investors Weigh In On Annexon
Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. JPMorgan Chase & Co. lifted its holdings in shares of Annexon by 23.9% during the first quarter. JPMorgan Chase & Co. now owns 91,090 shares of the company’s stock worth $249,000 after buying an additional 17,550 shares during the last quarter. Acadian Asset Management LLC acquired a new position in shares of Annexon during the first quarter worth approximately $388,000. Vanguard Group Inc. lifted its holdings in shares of Annexon by 1.8% during the first quarter. Vanguard Group Inc. now owns 1,095,032 shares of the company’s stock worth $2,990,000 after buying an additional 19,722 shares during the last quarter. Federated Hermes Inc. lifted its holdings in shares of Annexon by 50.7% during the first quarter. Federated Hermes Inc. now owns 3,052,651 shares of the company’s stock worth $8,334,000 after buying an additional 1,027,051 shares during the last quarter. Finally, XTX Topco Ltd acquired a new position in shares of Annexon during the first quarter worth approximately $100,000.
Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated neurodegeneration.
- Get a free copy of the StockNews.com research report on Annexon (ANNX)
- Monoclonal Antibodies? Avid Bioservices surges 32% on Blowout Q3
- GitLab Crashes On Guidance; Analysts Defend
- Healthcare Stocks With at Least 30 Years of Dividend Increases
- Coinbase Pops As SVB Crumbles To Dust
- Airlines Update Guidance, Shares Head For Different Destinations
Receive News & Ratings for Annexon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Annexon and related companies with MarketBeat.com's FREE daily email newsletter.